Piper Sandler raised the firm’s price target on Day One Biopharmaceuticals (DAWN) to $26 from $25 and keeps an Overweight rating on the shares following quarterly results. The firm thinks valuation provides an attractive entry point into Day One ahead of continued commercial execution, additional long-term data, and eventual 1L pLGG data in 2027.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DAWN:
- Day One Biopharmaceuticals Reports Strong Q3 2025 Growth
- Day One Biopharmaceuticals Reports Strong Q3 2025 Results
- Day One Biopharmaceuticals reports Q3 EPS (19c), consensus (28c)
- Day One Biopharmaceuticals, Inc. (DAWN) Q3 Earnings Cheat Sheet
- Day One Biopharmaceuticals’ Phase 3 Trial: A Potential Game Changer in Pediatric Glioma Treatment